, Feb. 20, 2014
/PRNewswire/ -- BDI Pharma today announced the launch of The MERREM Commitment Program with AstraZeneca, an assurance initiative offering customers security in product availability through contracted access to the original, branded MERREM®I.V. from AstraZeneca. Along with this innovative new partnership, BDI Pharma was awarded the status of Authorized Distributor of Record (ADR) for AstraZeneca and is the sole and exclusive distributor of contracted MERREM®I.V. in the United States
"We are excited about this new program and what it means to the healthcare community," stated Anthony Jackson, COO for BDI Pharma. "We are all aware that drug shortages can be costly, unpredictable, and potentially threaten patients' treatment. With The MERREM Commitment Program, our customers will have peace of mind that their institution has access to product now, and through potential shortages of generic meropenem."
Paired with the launch of this new program, BDI Pharma is offering a discounted introductory price on MERREM®I.V. to program participants for orders until June 30, 2014. Interested customers are encouraged to call 800-948-9834 for more information or visit http://bdipharma.com/Services-Merrem.aspx for details.
About BDI Pharma, Inc.
BDI Pharma has continuously refined the concept of niche distribution, providing solutions beyond the traditional wholesaler model since 1995. We operate as an extension of our partners' sales force, create demand, and move market share with each transaction. In this regard, we maintain a highly selective process when entering into a strategic partnership. Our approach of serving the manufactures as well as the customers over nearly two decades has proven successful in varied market conditions. This is further supplemented through innovative supply solutions, extensive product knowledge, 24/7 emergency availability and urgent need delivery. An open-access resource for reference material, educational literature, market data and online ordering, BDI Pharma's home web page www.bdipharma.com (also www.ivig.com) has become an industry-renowned point of reference. Proprietary programs covering comprehensive reimbursement services - www.bdiaccess.com and 855-BDI-CARE; and product consignment - www.bdivantageplus.com; round out a family of solutions tailored to the needs of the healthcare community at large.
BDI Pharma's product portfolio includes IVIG, branded and generic specialty pharmaceuticals, chemotherapy products, vaccines, albumin, coagulation factors, high-titer or "hyper" immune globulins, and other specialty injectables. BDI Pharma is recognized as an "ADR," or Authorized Distributor of Record, for all of the manufacturers it represents.
Read more news from BDI Pharma, Inc.
SOURCE BDI Pharma, Inc.